🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 15 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 26/08/1994 | 7,25 | 7,50 | 7,25 | 7,31 | -2,50% | 3,45% | 81.600 |
| 25/08/1994 | 7,25 | 7,56 | 7,00 | 7,50 | +3,45% | 7,76% | 126.000 |
| 24/08/1994 | 6,88 | 7,25 | 6,63 | 7,25 | +6,42% | 9,09% | 68.000 |
| 23/08/1994 | 6,88 | 6,88 | 6,75 | 6,81 | +0,00% | 1,82% | 3.800 |
| 22/08/1994 | 6,88 | 6,88 | 6,63 | 6,81 | +0,00% | 3,64% | 203.400 |
| 19/08/1994 | 6,88 | 6,88 | 6,75 | 6,81 | -0,91% | 1,82% | 128.000 |
| 18/08/1994 | 6,75 | 6,88 | 6,59 | 6,88 | +0,92% | 4,17% | 697.000 |
| 17/08/1994 | 6,88 | 7,25 | 6,75 | 6,81 | -6,03% | 7,27% | 278.200 |
| 16/08/1994 | 7,00 | 7,25 | 6,88 | 7,25 | +0,00% | 5,36% | 15.400 |
| 15/08/1994 | 6,69 | 7,25 | 6,63 | 7,25 | +0,00% | 9,35% | 65.800 |
| 12/08/1994 | 7,38 | 7,38 | 7,00 | 7,25 | -1,69% | 5,08% | 101.000 |
| 11/08/1994 | 7,25 | 7,50 | 7,13 | 7,38 | +1,72% | 5,17% | 251.200 |
| 10/08/1994 | 6,75 | 7,50 | 6,50 | 7,25 | +7,41% | 14,81% | 219.600 |
| 09/08/1994 | 6,13 | 6,75 | 6,13 | 6,75 | +10,20% | 10,20% | 119.600 |
| 08/08/1994 | 5,50 | 6,13 | 5,50 | 6,13 | +11,36% | 11,36% | 55.800 |
| 05/08/1994 | 5,88 | 5,88 | 5,50 | 5,50 | -4,35% | 6,38% | 20.800 |
| 04/08/1994 | 5,69 | 5,88 | 5,50 | 5,75 | +0,00% | 6,59% | 16.200 |
| 03/08/1994 | 5,75 | 5,75 | 5,50 | 5,75 | +4,55% | 4,35% | 81.600 |
| 02/08/1994 | 5,75 | 5,75 | 5,50 | 5,50 | -2,22% | 4,35% | 20.600 |
| 01/08/1994 | 5,75 | 5,75 | 5,50 | 5,63 | +0,00% | 4,35% | 5.600 |
| 29/07/1994 | 5,75 | 5,75 | 5,50 | 5,63 | +0,00% | 4,35% | 13.800 |
| 28/07/1994 | 5,25 | 5,63 | 5,25 | 5,63 | +2,27% | 7,14% | 82.600 |
| 27/07/1994 | 5,50 | 5,63 | 5,25 | 5,50 | +0,00% | 6,82% | 26.200 |
| 26/07/1994 | 5,63 | 5,75 | 5,50 | 5,50 | -2,22% | 4,44% | 45.800 |
| 25/07/1994 | 5,63 | 5,88 | 5,63 | 5,63 | -4,26% | 4,44% | 39.600 |
| 22/07/1994 | 5,88 | 5,88 | 5,88 | 5,88 | +0,00% | 0,00% | 12.000 |
| 21/07/1994 | 5,63 | 5,88 | 5,63 | 5,88 | +2,17% | 4,44% | 39.200 |
| 20/07/1994 | 5,63 | 5,88 | 5,63 | 5,75 | +0,00% | 4,44% | 21.800 |
| 19/07/1994 | 5,88 | 5,88 | 5,63 | 5,75 | +2,22% | 4,26% | 12.000 |
| 18/07/1994 | 5,88 | 5,88 | 5,63 | 5,63 | -4,26% | 4,26% | 19.200 |